#RNL2024 @RheumNow @_AprilArmstrong: Deucravacitinib v Apremilast Deucra: TYK2 inhibitor, approved for PsO (not yet PsA) Superior to apremilast for skin disease (sPGA) https://t.co/NRnsm4cOum